Lauren Bond
Family · Hanover, MDNPI 1073572970
Payments from drug & device makers
Across 59 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$112
- Merck$111
- Janssen Scientific Affairs, LLC$93
- AbbVie$92
- Astellas Pharma US Inc$90
- Novo Nordisk$86
- plus $680 from 20 others
What the payments were for
- Food & beverage$1,264100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 6 | $112 |
| Merck | 5 | $111 |
| Janssen Scientific Affairs, LLC | 1 | $93 |
| AbbVie | 4 | $92 |
| Astellas Pharma US Inc | 4 | $90 |
| Novo Nordisk | 5 | $86 |
| Sanofi Pasteur Inc. | 1 | $86 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Lilly USA, LLC | 4 | $68 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Tactile Systems Technology Inc | 3 | $60 |
| Pfizer | 3 | $55 |
| Amgen | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 2 | $27 |
| Watermark Medical, Inc. | 1 | $26 |
| Philips North America LLC | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Exact Sciences | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Organon | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
How this compares
$1,264 in reported general payments places this provider in the 75th percentile of 2,843 family providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 41 | $37,215 |
| JardianceEmpagliflozin | 20 | $29,645 |
| OzempicSemaglutide | 30 | $29,453 |
| MounjaroTirzepatide | 25 | $29,161 |
| JanuviaSitagliptin Phosphate | 22 | $23,073 |
| TradjentaLinagliptin | 12 | $14,744 |
| Rosuvastatin Calcium | 262 | $5,900 |
| MyrbetriqMirabegron | 12 | $5,754 |
| Atorvastatin Calcium | 253 | $4,462 |
| Metoprolol Succinate | 199 | $3,320 |
| Losartan Potassium | 197 | $2,430 |
| Levothyroxine Sodium | 177 | $2,170 |
| Bupropion XlBupropion Hcl | 45 | $2,077 |
| Pantoprazole Sodium | 122 | $2,008 |
| Omeprazole | 80 | $1,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $17 | $44,38932 claims |
| PfizerEliquis | $55 | $37,21541 claims |
| Novo NordiskOzempic | $86 | $29,45330 claims |
| Lilly USA, LLCMounjaro | $68 | $29,16125 claims |
| MerckJanuvia | $111 | $23,07322 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $5,75412 claims |
| AbbVieSynthroid | $92 | $1,54923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,843 family providers in Maryland.
Other family in Hanover
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
- Kristin AttiogbeChevy Chase$42K
- Sametta SanyaoluFulton$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.